Join our daily newsletter At The Bell to receive exclusive market insights
- A recent Optiscan Imaging (OIL) study shows the company’s technology is “extremely accurate” for the diagnosis of oral cancer and precancer
- The company has received interim results from its oral imaging study, where 47 patients were assessed via its real-time in-vivo confocal laser endomicroscope
- The diagnostic accuracy of the test was “extremely high” at 88.9 per cent for the presence of dysplasia or carcinoma, with 100 per cent of cancer cases correctly diagnosed
- The data is now being used to develop machine-learning algorithms for use in computer-assisted diagnoses and will support Optiscan’s US FDA application for its InVivage product for oral tissue imaging
- Optiscan Imaging shares are trading at 9.2 cents at 10:18 am AEDT
A recent Optiscan Imaging (OIL) study has demonstrated the company’s technology to be “extremely accurate” for the diagnosis of oral cancer and precancer.
The company has received the interim results of its oral imaging study, which was conducted at the Australian Centre for Oral Oncology Research and Education.
The data from 47 patients was assessed, who altogether presented with 63 oral mucosal lesions. From these patients, the Optiscan technology was able to diagnose squamous cell carcinoma and epithelial dysplasia via the company’s real-time in-vivo confocal laser endomicroscope (CLE).
The CLE images were captured live during clinical examination and assessed for the presence of cytological and architectural features of dysplasia and carcinoma, as determined by World Health Organisation diagnostic criteria.
Optiscan reported the diagnostic accuracy of the test was “extremely high” at 88.9 per cent for the presence of dysplasia or carcinoma, while also demonstrating 86.8 per cent sensitivity, 92 per cent specificity, 94.3 per cent positive predictive value, and 82.1 per cent negative predictive value.
Additionally, 100 per cent of cancer cases were diagnosed correctly using Optiscan’s CLE device.
“The results from this interim study show that Optiscan’s fluorescence-based CLE device is a highly accurate, easy-to-use, rapid and slide-free point-of-care optical imaging technology for diagnosing oral cancer and precancer,” Optiscan Chairman Robert Cooke said.
The company is now in the process of analysing the remaining data from this study to “maximise the utility” of its recently acquired IP.
The results are also being used to develop machine-learning algorithms for use in computer-assisted diagnosis and telepathology applications in the company’s partnership with Canadian-based Prolucid Technologies.
Additionally, these results, along with data contained within the company’s oral imaging datasets, will support Optiscan’s US Food and Drug Administration (FDA) De Novo Classification application for its InVivage product for oral tissue imaging.
Optiscan Imaging shares were trading at 9.2 cents at 10:18 am AEDT.
